Health economics in haemophilia: a review from the clinician’s perspective
Author:
- 23 April 2010
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 16 (s3) , 29-34
Abstract
Summary. Health economic evaluations provide valuable information for healthcare providers, facilitating the treatment decision‐making process in a climate where demand for healthcare exceeds the supply. Although an uncommon disease, haemophilia is a life‐long condition that places a considerable burden on patients, healthcare systems and society. This burden is particularly large for patients with haemophilia with inhibitors, who can develop serious bleeding complications unresponsive to standard factor replacement therapies. Hence, bleeding episodes in these patients are treated with bypassing agents such as recombinant activated FVII (rFVIIa) and plasma‐derived activated prothrombin complex concentrates (pd‐APCC). With the efficacy of these agents now well established, a number of health economic studies have been conducted to compare their cost‐effectiveness for the on‐demand treatment of bleeding episodes in haemophiliacs with inhibitors. In a cost‐utility analysis, which assesses the effects of treatment on quality of life (QoL) and quantity of life, the incremental cost per quality‐adjusted life‐year (QALY) gained (US $44 834) indicated that rFVIIa was cost‐effective. Similarly, eight of 11 other economic modelling evaluations found that rFVIIa was more cost‐effective than pd‐APCC in the on‐demand treatment of bleeding episodes. These findings indicate that treating patients with haemophilia promptly and with the most effective therapy available may result in cost savings.Keywords
This publication has 27 references indexed in Scilit:
- Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech RepublicHaemophilia, 2009
- A systematic review of the cost‐effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitorsHaemophilia, 2009
- Cost and outcome: Comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitorThrombosis and Haemostasis, 2008
- Recombinant Factor VIIa (Eptacog Alfa)PharmacoEconomics, 2007
- Current Opinion on Inhibitor Treatment OptionsSeminars in Hematology, 2006
- A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high‐titre inhibitorsHaemophilia, 2005
- Modelling the economic impact of recombinant activated Factor VII and activated prothrombin-complex concentrate in the treatment of a mild to moderate bleed in adults with inhibitors to clotting Factors VIII and IX at a comprehensive care centre in the UKJournal of Medical Economics, 2002
- Modelling the economic impact of recombinant activated Factor VII compared to activated prothrombin-complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting Factors VIII and IX in the UKJournal of Medical Economics, 2002
- THE DIAGNOSIS and MANAGEMENT OF FACTOR VIII and IX INHIBITORS: A GUIDELINE FROM THE UK HAEMOPHILIA CENTRE DOCTORS' ORGANIZATION (UKHCDO)British Journal of Haematology, 2000
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990